For the Treatment of Chronic Tophaceous Gout, a Drug That Resolves Tophi in Less Than One Year Would Become the Patient Share Leader in the U.S. and Europe

Monday, January 11, 2010 Drug News
Email Print This Page Comment bookmark
Font : A-A+

Savient Pharmaceuticals' Krystexxa Will Become Decision Resources' Clinical Gold Standard in 2013

Gisselle Morales

Elizabeth Marshall

Decision Resources

Decision Resources, Inc.

781-296-2691

781-296-2563

[email protected]

[email protected]



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store